alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 401–425 of 612 studies with an author at Johns Hopkins University (US) (page 17 of 25) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Archives of pathology & laboratory medicine 2001-04-01

We propose the following sequence of events in the development of neuropathologic changes of Alzheimer disease in Down syndrome: (1) intracellular accumulation of Abeta in neurons and astrocytes, (2) deposition of extracellular Abeta and formation of diffuse plaques, and (3) development of neuritic plaques and neurofibrillary tangles with activation of microglial cells. 1 key finding →

Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. NeuroImage 2004-05-01

The study aimed at mapping (i) the distributed electroencephalographic (EEG) sources specific for mild Alzheimer's disease (AD) compared to vascular dementia (VaD) or normal elderly people (Nold) and (ii) the distributed EEG sources sensitive to the mild AD at different stages of severity. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2022-01-03

The association of testosterone concentrations with dementia risk remains uncertain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Annals of neurology 1993-09-01

The cause of acquired immunodeficiency syndrome (AIDS) dementia, which is a frequent late manifestation of human immunodeficiency virus (HIV) infection, is unknown but radiological and pathological studies have implicated alterations in subcortical white matter. 4 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Why has therapy development for dementia failed in the last two decades?

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-12-19

The success rate of the pharmaceutical research and development (R&D) for dementia drugs has been abysmally low, in the last two decades. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The measurement of cognition in large-scale cross-national surveys: lessons from the Health and Retirement Study International Network of Studies and the Harmonized Cognitive Assessment Protocol

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Journals of Gerontology Series B 2025-10-16

These lessons emphasize the importance of ensuring tests are feasible across both high-income countries and LMICs, maintaining consistency within studies and over time, and designing comprehensive cognitive batteries for improved measurement precision of general and domain-specific phenotypes. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. International Psychogeriatrics 2026-01-01

In the ADMET2 biomarker subset (n = 44, MPH:21, age:75 years, MMSE:20.2), higher baseline TNF was associated with higher M6 NPI-A [B(SE)= 6.86 (1.71), p = .0003], and multivariable models found lower baseline TNF [B(SE)= 8.28(1.61), p < .001] and higher baseline S100B [B(SE)= -6.41(1.95), p = .002] were associated with lower M6 NPI-A. Exploratory analyses suggested that higher baseline NfL significantly interacted with treatment to predict lower M6 NPI-A [B(SE)= -8.36(4.21), p = .05], only when adjusting for cognition. 5 key findings →

Participants: 44 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The cardiovascular health study: Design and rationale

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Annals of Epidemiology 1991-02-01

The Cardiovascular Health Study is a population-based, longitudinal study designed to evaluate factors related to the onset, course, and risk of coronary heart disease and stroke in adults aged 65 years and older. 4 key findings →

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment. Cognitive training in older adults: lessons from the ACTIVE Study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Current Alzheimer research 2009-08-01

This paper is based on a presentation made during the Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment on April 19, 2008. 3 key findings →

Participants: 3,000 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Modifiable factors that alter the size of the hippocampus with ageing

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature reviews. Neurology 2012-03-13

The hippocampus is particularly vulnerable to the neurotoxic effects of obesity, diabetes mellitus, hypertension, hypoxic brain injury, obstructive sleep apnoea, bipolar disorder, clinical depression and head trauma. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of neurology 2012-09-01

Increased connectivity after 1 year of DBS is observed, which is in contrast to the decreased connectivity observed over the course of AD. 2 key findings →

Design: open-label trial Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Recovery of activities of daily living in older adults after hospitalization for acute medical illness

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of the American Geriatrics Society 2008-12-01

By 12 months after discharge, of those discharged with new or additional ADL disability, 41.3% died, 28.6% were alive but had not recovered to baseline function, and 30.1% were at baseline function. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus

✓ Peer-reviewed alzhub usefulness score 50 out of 100. International psychogeriatrics 2018-08-02

ABSTRACTObjectives:Behavioral and psychological symptoms of dementia (BPSD) are nearly universal in dementia, a condition occurring in more than 40 million people worldwide. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

HIV-associated cognitive impairment before and after the advent of combination therapy

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurovirology 2002-04-01

The objective of this study was to describe the occurrence of HIV dementia and neuropsychological testing abnormalities in a new cohort of HIV-seropositive individuals at high risk for HIV dementia and to compare these results to a cohort before the advent of highly active antiretroviral therapy (HAART). 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Scientific reports 2019-02-19

In the Alzheimer's disease (AD) continuum, the prodromal state of mild cognitive impairment (MCI) precedes AD dementia and identifying MCI individuals at risk of progression is important for clinical management. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The changing scene of amyotrophic lateral sclerosis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature reviews. Neuroscience 2013-03-06

Several recent breakthroughs have provided notable insights into the pathogenesis of amyotrophic lateral sclerosis (ALS), with some even shifting our thinking about this neurodegenerative disease and raising the question as to whether this disorder is a proteinopathy, a ribonucleopathy or both. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuron 1999-11-01

Filamentous tau aggregates are hallmarks of tauopathies, e.g., frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1990-02-01

In the brains of aged humans and cases of Alzheimer disease, deposits of amyloid in senile plaques are located in proximity to nerve processes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Metabolomics and cognition in African American adults in midlife: the atherosclerosis risk in communities study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Translational psychiatry 2017-07-18

Clinical studies have shown alterations in metabolic profiles when patients with mild cognitive impairment and Alzheimer's disease dementia were compared to cognitively normal subjects. 4 key findings →

Participants: 1,534 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Perspectives on depression, mild cognitive impairment, and cognitive decline

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of general psychiatry 2006-02-01

Cognitive impairment and late-life depression are associated with increased risk for subsequent dementia; however, investigations of these phenomena appear to be proceeding along separate tracks. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed